# National Cancer Center Hospital East

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/national-cancer-center-hospital-east/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 53 |
| Citations | 1,630,863 |
| City | Kashiwa |
| Country | JP |
| Description | National Cancer Center Hospital East is a research organisation in Kashiwa, JP. OpenAlex records 17,467 works and 1,630,863 citations for it. 3,112 researchers list it as their most recent affiliation. |
| Homepage | https://www.ncc.go.jp/en/ncce/index.html |
| OpenAlex ID | https://openalex.org/I4210145079 |
| Researchers | 3,112 |
| ROR ID | https://ror.org/03rm3gk43 |
| Type | healthcare |
| Works | 17,467 |

## University papers

Showing 12 of 95.

- [Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck](https://scholariq.org/papers/nivolumab-for-recurrent-squamous-cell-carcinoma-of-the-head-and-neck/)
- [Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study](https://scholariq.org/papers/pembrolizumab-alone-or-with-chemotherapy-versus-cetuximab-with-chemotherapy-for/)
- [Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer](https://scholariq.org/papers/lenvatinib-versus-placebo-in-radioiodine-refractory-thyroid-cancer/)
- [The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)](https://scholariq.org/papers/the-japanese-society-of-hypertension-guidelines-for-the-management-of/)
- [Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer](https://scholariq.org/papers/osimertinib-in-resected-i-egfr-i-mutated-non-small-cell-lung-cancer/)
- [Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial](https://scholariq.org/papers/segmentectomy-versus-lobectomy-in-small-sized-peripheral-non-small-cell-lung/)
- [Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study](https://scholariq.org/papers/pembrolizumab-plus-chemotherapy-versus-chemotherapy-alone-for-first-line/)
- [Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer](https://scholariq.org/papers/randomized-phase-iii-keynote-181-study-of-pembrolizumab-versus-chemotherapy-in/)
- [Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer](https://scholariq.org/papers/perioperative-pembrolizumab-for-early-stage-non-small-cell-lung-cancer/)
- [Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials](https://scholariq.org/papers/larotrectinib-in-patients-with-trk-fusion-positive-solid-tumours-a-pooled/)
- [Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial](https://scholariq.org/papers/alectinib-versus-crizotinib-in-patients-with-alk-positive-non-small-cell-lung/)
- [Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort](https://scholariq.org/papers/antitumor-activity-of-pembrolizumab-in-biomarker-unselected-patients-with/)

## University researchers

- [Kōichi Goto](https://scholariq.org/researchers/koichi-goto/)
- [Kiyotaka Yoh](https://scholariq.org/researchers/kiyotaka-yoh/)
- [Yusuke Okuma](https://scholariq.org/researchers/yusuke-okuma/)
- [Kae Okuma](https://scholariq.org/researchers/kae-okuma/)
- [Yasuaki Ohtaki](https://scholariq.org/researchers/yasuaki-ohtaki/)
- [Takuya Kuriyama](https://scholariq.org/researchers/takuya-kuriyama/)

## University top topics

Showing 8 of 25.

- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Esophageal Cancer Research and Treatment](https://scholariq.org/topics/esophageal-cancer-research-and-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.